menu search

Kineta reports third quarter 2023 financial results and provides corporate update

Announced positive KVA12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial Enrolled the first patient of KVA12123 in comb...

November 3, 2023, 8:01 pm

Atossa therapeutics' (z)-endoxifen being evaluated as alternative treatment for ductal carcinoma in situ

Atossa Therapeutics Inc (NASDAQ:ATOS)'s selective estrogen receptor modulator (Z)-endoxifen is being ev...

October 30, 2023, 3:11 pm

Reneo pharmaceuticals announces poster presentation at upcoming scientific meetings

IRVINE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the ...

October 25, 2023, 11:50 am

Carisma to present first results from in vivo car-m collaboration with moderna at sitc 2023

-Late-breaking abstract to be presented on November 3 rd at 11:30 am PT highlighting pre-clinical data with Moderna -Two additional pre-clinical data ...

October 25, 2023, 9:11 am

Altimmune to present new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide in a late-breaking presentation at the liver meeting® 2023

GAITHERSBURG, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that n...

October 25, 2023, 7:30 am

Merck's keytruda shows positive results in confirmatory trial as treatment for rare form of esophageal cancer

Merck & Co. MRK, -1.53% said Friday a late-stage trial of its blockbuster cancer drug Keytruda plus trastuzumab, fluoropyrimidine- and platinum-contai...

October 20, 2023, 8:13 am

Why is viking therapeutics (vktx) stock moving today?

Viking Therapeutics (NASDAQ: VKTX ) stock is on the move Wednesday as the clinical-stage biopharmaceutical company reveals data from a clinical trial....

October 18, 2023, 10:01 am

Viking therapeutics joins weight loss drug bandwagon as trial data impresses

Viking Therapeutics (NASDAQ:VKTX) shares shot up 12% in overnight US trading as the drug developer revealed more impressive trial data from a treatmen...

October 18, 2023, 7:06 am

Arvinas and pfizer announce upcoming vepdegestrant (arv-471) poster presentation at esmo congress 2023

NEW HAVEN, Conn. and NEW YORK, Oct. 15, 2023 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will p...

October 15, 2023, 10:05 pm

Pharvaris to present at the apaaaci 2023 international conference

ZUG, Switzerland, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 ...

October 13, 2023, 6:50 am

Immunic presents data from phase 2 study of vidofludimus calcium in relapsing-remitting ms

Immunic Inc (NASDAQ:IMUX) announced that data from its Phase 2 EMPhASIS trial of nuclear receptor-relat...

October 11, 2023, 10:11 am

Pharvaris to present at the ciic fall 2023 conference

ZUG, Switzerland, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-...

October 4, 2023, 7:34 am

Cancer drug approval? 3 biotech stocks on the brink of breakthroughs

Autologous chimeric antigen receptor T cell therapy is 0ne of the most promising, relatively new types ...

October 2, 2023, 7:09 pm

$vktx: consolidation in viking therapeutics provides an opportunity

Viking Therapeutics Inc. is an innovative biotechnology company developing novel therapeutics for metabolic and endocrine diseases. Metabolic and rare...

October 2, 2023, 6:17 pm

Structure therapeutics stock soars on positive weight loss data

Structure Therapeutics Inc shares surged 34% to $50.34 in midday trading on Friday after the clinical-stage global biopharmaceutical company announced...

September 29, 2023, 12:55 pm

Pharvaris to participate in the 2023 cantor global healthcare conference

ZUG, Switzerland, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-...

September 19, 2023, 6:50 am

Vigil neuroscience: interesting early data, wait for phase 2

Vigil Neuroscience is developing medicines for neurodegenerative diseases by restoring microglial function. Their lead candidate, VGL101, is a monoclo...

September 18, 2023, 2:38 pm

Io therapeutics, inc., announces publication of data on a novel compound promoting anti-cancer immune responses

SPRING, Texas, Sept. 12, 2023 (GLOBE NEWSWIRE) — Io Therapeutics, Inc., announced today the publication in Scientific Reports – Nature Publishing ...

September 12, 2023, 4:43 am

Pharvaris to present at the 18th german allergy congress

ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-...

September 6, 2023, 6:51 am

Pharvaris to participate in the morgan stanley 21st annual global healthcare conference

ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-...

September 6, 2023, 6:50 am


Search within

Pages Search Results: